Cleared Traditional

K875366 - THE DDI SERODOT HERPES IGG TEST KIT

K875366 is an FDA 510(k) clearance for THE DDI SERODOT HERPES IGG TEST KIT, manufactured by Disease Detection International, Inc.. The device is a Class 2 Microbiology device with product code GQO cleared through the Traditional 510(k) pathway after a 144-day FDA review.

K875366 · Disease Detection International, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1988
Decision
144d
Days
Class 2
Risk

K875366 is an FDA 510(k) clearance for the THE DDI SERODOT HERPES IGG TEST KIT. Classified as Antisera, Cf, Herpesvirus Hominis 1,2 (product code GQO), Class II - Special Controls.

Submitted by Disease Detection International, Inc. (Irvine, US). The FDA issued a Cleared decision on May 23, 1988 after a review of 144 days - within the typical 510(k) review window.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3305 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Disease Detection International, Inc. devices

FDA 510(k) Submission Details - K875366

510(k) Number K875366 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 31, 1987
Decision Date May 23, 1988
Days to Decision 144 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
42d slower than avg
Panel avg: 102d · This submission: 144d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GQO Device Classification - Class 2, Special Controls

Product Code GQO Antisera, Cf, Herpesvirus Hominis 1,2
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3305
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - GQO Antisera, Cf, Herpesvirus Hominis 1,2

All 9
Devices cleared under the same product code (GQO) and FDA review panel - the closest regulatory comparables to K875366.
VIROGEN HSV ANTIBODY TEST
K871426 · Armkel, LLC · Oct 1987
VISIBLE-HERPES TM TEST SYSTEM
K854712 · Isolab, Inc. · May 1986
HSV2 - IGG ELISA-KIT
K852781 · Clinical Sciences, Inc. · Jan 1986
HSVI - IGG ELISA-KIT
K852782 · Clinical Sciences, Inc. · Jan 1986
AMIZYME-HSV TYPES 1 & 2 TEST KITS
K842531 · Amico Lab, Inc. · Dec 1985
ANTI-HERPES SIMPLEX VIRUS TYPE 1 OR 2
K842663 · Amico Lab, Inc. · Dec 1985